Disease burden of neovascular age-related macular degeneration and diabetic macular edema.

Almony A. Am J Manag Care. 2023;29(suppl 6):S75-S80.

Updates on novel and traditional OCT and OCTA biomarkers in nAMD.

Crincoli E, Parravano MC, Sacconi R, et al. Eye. 2025;39(9):1662-1672.

Intravitreal aflibercept 8 mg for diabetic macular edema: ninety-six-week results from the randomized phase 2/3 PHOTON trial.

Do DV, Wykoff CC, Sivaprasad S, et al. Ophthalmology. 2026;133(5):577-588.

Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis.

Garweg JG, Gerhardt C. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2181-2192.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Heier JS, Khanani AM, Quezada Ruiz C, et al. Lancet. 2022;399(10326):729-740.

A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration.

Heloterä H, Kaarniranta K. Cells. 2022;11(21):3453.

Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT.

Müller S, Junker S, Wilke T, et al. Int J Retina Vitreous. 2021;7(1):43.

Standardization of OCT angiography nomenclature in retinal vascular diseases: consensus-based recommendations.

Munk MR, Turgut F, Faes L, et al. Ophthalmol Retina. 2025;9(7):645-654.

Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration.

Sobolewska B, Sabsabi M, Ziemssen F. Clin Ophthalmol. 2021;15:4317-4326.

Molecular and cellular mechanisms involved in the pathophysiology of retinal vascular disease—interplay between inflammation and oxidative stress.

Srejovic JV, Muric MD, Jakovljevic VL, et al. Int J Mol Sci. 2024;25(21):11850.

Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII).

Wang R, McClard CK, Laswell S, et al. BMJ Open Ophthalmol. 2022;7(1):e001188.

Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials.

Wong TY, Haskova Z, Asik K, et al. Ophthalmology. 2024;131(6):708-723.